3rd World ADC Asia
pharmaphorum
FEBRUARY 8, 2024
Optimising Physiochemical, Potency & Impurity Analytical Methods to Ensure Regulatory Compliance
world asia 
Launch of world-first expert resource to foster best practice osteoporosis care in the Asia Pacific
Pharma Mirror
OCTOBER 22, 2021
New Delhi, India, More than 50 per cent of the world’s hip fractures are expected to occur in the Asia Pacific by the year 2050. The post Launch of world-first expert resource to foster best practice osteoporosis care in the Asia Pacific appeared first on Pharma Mirror Magazine.
52 Join 18,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
WHO’s top scientist learned a hard lesson about H5N1 two decades ago: Stopping it takes more than biology
STAT
MAY 7, 2024
Jeremy Farrar, now the World Health Organization’s chief scientist, was working in Vietnam 20 years ago when the H5N1 virus started to spread across Asia — at that point in poultry. He recalls there was a reluctance among farmers to cull their chickens because they weren’t being compensated for them.
141 
Fierce Pharma Asia—Leqembi’s slow uptake; Takeda’s pipeline culls; Roche’s world-first nod
Fierce Pharma
FEBRUARY 8, 2024
Roche's subcutaneous C5 inhibitor won its world-first approval in China. . | Eisai said uptake of its Biogen-partnered Alzheimer's drug, Leqembi, will likely miss an early launch target. Takeda cut several cancer candidates in its latest pipeline clear-out. And more.
52 
Fierce Pharma Asia—Carvykti faces FDA adcomm; AZ drug picks up world-first approval; Samsung Bio's year of growth
Fierce Pharma
JANUARY 25, 2024
AstraZeneca has won a world-first approval for its rare blood disorder add-on therapy in Japan. The FDA will convene an advisory committee to discuss Johnson & Johnson and Legend's Carvykti filing in earlier multiple myeloma. | Samsung Biologics tallied an “exceptional” year in 2023. And more.
FDA 89
89 FDA 89
89 
STAT+: Even with gene therapy on the horizon, drugmakers join hunt for new sickle cell drugs
STAT
DECEMBER 19, 2022
And they require too much medical infrastructure to be given in most of South Asia and West Africa, where most of the world’s roughly 120 million sickle cell patients live. and Europe. Continue to STAT+ to read the full story…
98 
STAT+: Pharmalittle: Chinese drugmakers develop copycat weight loss drugs; SEC eyes supplier of research monkeys
STAT
AUGUST 16, 2023
… Chinese pharmaceutical companies are developing domestic versions of “miracle” weight-loss drugs as they take on Western drugmakers selling anti-obesity medication in one of the world’s biggest markets , The Financial Times tells us. And the SEC wants to know whether Inotiv complied with the U.S.
Thermo Fisher Scientific opens sterile drug facility in Singapore
Pharmaceutical Technology
MAY 22, 2023
Thermo Fisher Scientific has expanded its sterile manufacturing and research capabilities in the Asia-Pacific region with the opening of a new sterile drug facility in Singapore. The new good manufacturing practices facility was established with support from the Singapore Economic Development Board.
Vaccines 59
59 Vaccines 59
59 
Novo Holdings leads $200m financing into Esco Lifesciences Group
pharmaphorum
MAY 27, 2021
Funds will be used to expand the company’s presence across Asia and create an innovation hub in Boston for cell and gene therapy technologies. The deal was described by the companies as the largest private financing round for an Asia-based life sciences tools company.
57 
Singapore accepts Everest’s NDA for IgA nephropathy treatment
Pharmaceutical Technology
APRIL 6, 2023
Everest Medicines CEO Rogers Yongqing Luo said: “This milestone is a testament to Everest’s ability to successfully advance much-needed, first-in-disease drug candidates through regulatory pathways across multiple regions in Asia, as we work to bring critical treatment options to patients as quickly as possible. “We
52 
Pharma pollution ‘threatens world environment, health’; study
pharmaphorum
FEBRUARY 15, 2022
One in four of the world’s rivers are polluted with potentially toxic levels of pharma compounds, according to a new study. The post Pharma pollution ‘threatens world environment, health’; study appeared first on. The research is published in the Proceedings of the National Academy of Sciences journal.
Compounding 104
104 Compounding 104
104 
Asia-Pacific Regulatory & Industry Views on Drug Shortage Prevention
ISPE
MAY 22, 2023
The webinar was moderated by Vivien Santillan, Regional Director, Asia, Novatek International. Regulatory speakers were Lisa Hedman, Group Lead for the Division of Supply and Access to Medicines of the World Health Organization (WHO); and Joyce Cirunay, Director IV of the Center for Drug Regulation and Research at the Philippines FDA.
Eli Lilly to help fund cold chain initiative
European Pharmaceutical Review
JANUARY 27, 2023
The investment will enable an estimated 150 medical-grade refrigeration units to be installed at 25 Life for a Child partner facilities in Africa, Latin America, the Caribbean and Southeast Asia. Cold chain – a vital part of medical logistics Cold chain refers to the transportation and storage of temperature-controlled medications.
Samsung Biologics recognised for sustainable growth
European Pharmaceutical Review
AUGUST 11, 2022
The Enlightened Growth Leadership Awards recognise organisations that are committed to making the world a better place and that are part of the solution to global challenges. It considers the synergy between growth, corporate social responsibility (CSR) and ESG.
Vaccines 106
106 Vaccines 106
106 
Country focus: China & APAC’s growing medical needs bring opportunities and challenges
pharmaphorum
JUNE 8, 2021
Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating this enormous market. Home to over 60% of the world’s population, Asia Pacific (APAC) is not a region the biopharma industry can afford to ignore. Mei uses China as an example.
Chemotherapy 104
104 
A List Of Antimicrobial Stewardship and Infectious Diseases Conferences and Meetings
IDStewardship
MAY 21, 2023
BCPS, BCIDP Article Posted May 2023 There are many infectious diseases conferences and meetings that take place around the world each year. On this webpage, a list of antimicrobial stewardship and infectious diseases conferences and meetings is provided. List Composed By: Timothy P. Gauthier, Pharm.D.,
Chemotherapy 130
130 Chemotherapy 130
130 
Novotech Sponsors Endpoints ASCO 2022 Expert Panel on Accelerating Oncology Clinical Trials in China
Pharma Mirror
JUNE 8, 2022
According to the Endpoints ASCO session: “China and the US are the world’s largest oncology research destinations, and the. The post Novotech Sponsors Endpoints ASCO 2022 Expert Panel on Accelerating Oncology Clinical Trials in China appeared first on Pharma Mirror Magazine.
52 
Emmes and MedGenome Launch Genomics Strategic Partnership Focused on Advancing Rare Disease Research
Pharma Mirror
NOVEMBER 16, 2021
Rockville, Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced a partnership with MedGenome aimed at accelerating breakthrough treatments, powered by human genomics, for rare disease patients.
52 
Pharma contract manufacturing market to grow to $130bn by 2026
European Pharmaceutical Review
AUGUST 19, 2022
Based on region, China, the world`s second largest economy, is forecast to reach a projected market size of $21.1 Lower labour costs, presence of significant talent pool and growing domestic markets are some of the factors driving growth in the Asia-Pacific region. Within the $130.2 billion, growing at a CAGR of 4.4 percent CAGR.
Packaging 93
93 
Cannabinoids receptors: popular preclinical target but banned in 137 countries
Pharmaceutical Technology
DECEMBER 5, 2022
In the US, the world’s largest pharmaceutical market, most states have legalized cannabinoids for medical use. In Asia, Africa and the Middle East, cannabinoid-based drugs are mostly illegal and continue to present a major regulatory obstacle.
Alzheimer’s therapeutics market to reach $6.8 billion by 2032
European Pharmaceutical Review
DECEMBER 16, 2022
The research segmented the market regionally as North America, Europe, Asia Pacific, Latin America, Middle East & Africa and the Rest of the World. According to World Alzheimer Report in 2015, regional estimations of dementia prevalence in people aged 60 years and over vary from 4.6 percent in Central Europe to 8.7
Compounding 86
86 
AstraZeneca Receives EMA’s CHMP Positive Opinion Recommending Marketing Authorization of Ultomiris (ravulizumab) for Neuromyelitis Optica Spectrum Disorder
PharmaShots
APRIL 3, 2023
Shots: The EMA’s CHMP has recommended Ultomiris for marketing authorization in the EU for adult patients with NMOSD who are anti-aquaporin-4 Ab+ The opinion was based on the P-III trial (CHAMPION-NMOSD) evaluating Ultomiris in 58 patients across North America, the EU, Asia-Pacific & Japan.
40 
AstraZeneca’s Ultomiris (ravulizumab) Receives the MHLW’s Approval for the Prevention of Relapses in Patients with NMOSD
PharmaShots
MAY 29, 2023
neuromyelitis optica The approval was based on the P-III trial (CHAMPION-NMOSD) evaluating Ultomiris in 58 patients across North America, the EU, Asia-Pacific & Japan. The safety & tolerability were consistent with prior studies & real-world use with no new safety signals.
40 
AstraZeneca’s Ultomiris (ravulizumab) Receives EC’s Approval for the Treatment of Neuromyelitis Optica Spectrum Disorder in EU
PharmaShots
MAY 11, 2023
& the safety & tolerability was consistent with prior studies and real-world use with no new safety signals. in relapse risk reduction) and continuing through a median duration of 90wks. in relapse risk reduction) and continuing through a median duration of 90wks.
40 
Pfizer to reach carbon net-zero by 2040
European Pharmaceutical Review
JULY 5, 2022
The window is closing to minimise the potentially catastrophic impact of climate change, which affects the health of our planet and that of people around the world,” commented Pfizer’s Chairman and Chief Executive Officer, Albert Bourla. WHClimatePledge. — Pfizer Inc. pfizer) June 30, 2022.
Scivita Medical Raises Nearly RMB0.4 Billion in Series A Funding Round and Strives to Build A World-leading Platform for Innovative Products in Endoscope and Related Fields
Pharma Mirror
APRIL 27, 2021
The investment was jointly led by GL Ventures and Lilly Asia Ventures, with contribution from Matrix Partners China, Medtronic, Chengwei Capital and Shanghai Innochip Investment. . (“Scivita Medical”) announced that it has raised nearly RMB0.4 The post Scivita Medical Raises Nearly RMB0.4
52 
Staying In for Pandemic Lockdowns Resulted in More Nearsighted Children
The People's Pharmacy
MARCH 23, 2023
Parents aroung the world are trying to help kids catch up on the schooling they may have missed. Pre-Pandemic Concerns About Kids’ Vision: Nearsightedness has become an epidemic eye problem among children in East and Southeast Asia. This focusing problem has also been increasing at an alarming rate around the world.
72 
Dental implant market: Top trends bolstering industry growth
pharmaphorum
AUGUST 9, 2021
People across the world, especially the population aged 65 years or older, are suffering from some form of a medical condition that results in tooth decay or loss. Growing use of CAD/CAM technologies in Asia Pacific: Advanced technologies like CAD/CAM are experiencing widespread use in dental implants market in Asia Pacific.
Hospitals 98
98 Hospitals 98
98 
Antibiotics ‘no longer effective’ for childhood infections, finds study
European Pharmaceutical Review
NOVEMBER 2, 2023
Research led by the University of Sydney has found that many antibiotics recommended by the World Health Organization (WHO) had “less than 50 percent effectiveness” in treating childhood infections such as pneumonia, sepsis and meningitis.
Hospitals 91
91 Hospitals 91
91 
FDA approves Ipsen’s Bylvay for cholestatic pruritus due to ALGS
Pharmaceutical Technology
JUNE 14, 2023
“We are proud to have achieved FDA approval for Bylvay as a treatment for ALGS in the US and we are committed to making it available to many more eligible patients across the world.”
FDA 52
52 FDA 52
52 
Surprise pandemic lessons for pharma
pharmaphorum
JULY 30, 2021
Residents of Southeast Asia who had experienced the SARS outbreak in 2002-04 would likely have had a much better understanding, but even they could not have imagined just how disorganised the response would be in many other parts the world. It also continues to surprise us. The vaccines’ success.
Vaccines 52
52 Vaccines 52
52 
FDA starts speedy review of Takeda’s dengue vaccine
pharmaphorum
NOVEMBER 23, 2022
Dengue is a mosquito-borne virus endemic in more than 125 countries, including the US territories of Puerto Rico, the US Virgin Islands, and American Samoa, and is a leading cause of fever among travellers to Latin America, the Caribbean, and Southeast Asia.
Vaccines 120
120 
AstraZeneca’s Ultomiris receives Japanese approval for NMOSD
Pharmaceutical Technology
MAY 28, 2023
Designed to assess the efficacy and safety of Ultomiris in adults with NMOSD, the open-label and multicentre CHAMPION-NMOSD study recruited 58 patients across Europe, North America, Asia-Pacific and Japan.
Labelling 52
52 Labelling 52
52 
Four ways Biogen is tackling digital innovation in neurological disease
pharmaphorum
DECEMBER 11, 2022
So, when a life sciences company embarks on a project of digital transformation or innovation, it’s really embarking on multiple projects that span the wide world of pharmaceutical operations. We are bringing the two worlds together to work on digital innovation. Dr Yacine Hadjiat is global head of Biogen Digital Health Solutions.
Hospitals 137
137 Hospitals 137
137 
COVID antibodies from Roche, Celltrion backed for approval in EU
pharmaphorum
NOVEMBER 12, 2021
The World Health Organization said yesterday that the moment the Europe/Central Asia region is the only one in the world where COVID-19 cases and death rates are on the increase, with a 10% increase in mortality over the last week. The post COVID antibodies from Roche, Celltrion backed for approval in EU appeared first on.
98 
Assessing the scale of pharmaceutical crime using API content
European Pharmaceutical Review
AUGUST 26, 2022
Likely substandard medicines (those with <80 percent API) were most commonly reported in Africa, followed by Asia. On the other hand, likely falsified medicines (those containing <50 percent API) were more prevalent in Asia (23.4 percent of samples) than Africa (11.4 percent of all poor-quality samples, respectively.
Potential and Challenges of the APAC Pharmaceutical Industry
Viseven
JUNE 12, 2023
Though we’re witnessing fundamental changes all over the world, each region has its peculiarities dictated by multiple local factors. Main Potential of Pharma in the Asia-Pacific Region What role does the APAC region play in transforming today’s worldwide pharma market? What’s Next for Customer Experience? —
COVID-19 health concern declines in June: Poll
Pharmaceutical Technology
JULY 7, 2022
New COVID-19 cases declined by 12% between 30 May and 05 June, according to the World Health Organization (WHO) data. The Eastern Mediterranean, the South-East Asia, and the Americas reported increases in new weekly cases by 58%, 33%, and 13% respectively, while new weekly cases decreased in Europe, Africa, and the Western Pacific Region.
59 Asia Pacific’s five largest chemical and pharmaceutical construction projects that commenced in Q2 2022
Pharmaceutical Technology
JULY 28, 2022
Here are Asia Pacific’s five largest chemical and pharmaceutical construction projects that were initiated in Q2 2022, according to GlobalData’s construction projects database. The main aim is to produce innovative vaccines on a massive scale for Asia and respond to future pandemic risks.
Vaccines 40
40 Vaccines 40
40 
Re-designing and Transforming PV for Augmenting Patient Safety
PharmaShots
APRIL 27, 2023
Multi-Country Safety Head – South Asia & Indo-China (Vietnam), Sanofi, India Naveen Chhabra, Global Medical Safety Lead, Global Drug Development, Novartis, India Varun Dua, Vice President -Professional Services, RxLogix, India Dhanaraj E, Pharmacovigilance Lead- CDMA-BBL, Biocon, India Kanchan Kanitkar, Sr.
FDA 40
40 
China’s NMPA approves AstraZeneca’s Soliris to treat gMG
Pharmaceutical Technology
JUNE 14, 2023
“We remain committed to expanding access to innovative therapies for rare disease patients in China and around the world.” The regulatory approval was based on comprehensive data obtained from the Phase III REGAIN trial conducted in 125 patients across South America, North America, Europe and Asia.
Labelling 52
52 
Shionogi and MPP enter Covid-19 antiviral licensing deal
Pharmaceutical Technology
OCTOBER 4, 2022
Shionogi will waive royalty payments on product sales in all countries under this deal as long as Covid-19 is listed by the World Health Organization as a Public Health Emergency of International Concern. In the Phase III portion of a Phase II/III clinical trial in Asia, ensitrelvir met the primary endpoint.
59 
WuXi STA breaks ground on new Delaware manufacturing facility
European Pharmaceutical Review
AUGUST 17, 2022
WuXi STA has 12 sites across the US, Europe and Asia. This campus is only possible because of Delaware’s world-class, innovative workforce. The WuXi STA Middletown site is located in the Middletown Business Center at 1091 Industrial Drive and facility will create approximately 500 full-time jobs by 2026.
Packaging 79
79 
Further, Trustedoctor merge to provide ‘borderless’ healthcare
pharmaphorum
JANUARY 5, 2021
Further – which was rebranded from BDU International last year – specialises in providing cross-border health insurance to people across Europe, the Middle East, Africa and Asia, and according to CEO Frank Ahedo aims to provide people with access to healthcare “no matter what the location or cost.”.
Insurance 57
57 
Let's personalize your content